Juq-934 Instant

The community has already contributed over 2,000 open‑source kernels, and the JUQ‑934 Forum now hosts more than 15 k active members.

If you’re curious about the next generation of compute, schedule a demo with QuantumEdge or spin up a trial instance on AWS today. The quantum future isn’t tomorrow—it’s right now, and it’s called JUQ‑934.

Stay tuned to TechFrontiers for deep‑dives into the JUQ‑934 ecosystem, interview with the architects, and hands‑on tutorials. JUQ-934

A global shipping company applied JUQ‑934 to a dynamic vehicle‑routing problem with stochastic demand. The hybrid algorithm continuously re‑optimizes routes in near‑real time, cutting fuel consumption by 8 % and improving delivery punctuality.

| Property | Value | |----------|-------| | IUPAC name | 3‑[(4‑fluorophenyl)amino]‑2‑[(1‑methyl‑1H‑imidazol‑5‑yl)methyl]‑5‑(trifluoromethyl)‑1,4‑dihydro‑pyridine‑6‑carboxamide | | Synonyms | JUQ‑934; 4‑F‑BETA‑3; PTC‑938 | | Molecular formula | C₁₈H₁₈F₄N₅O | | Molecular weight | 387.33 g·mol⁻¹ | | SMILES | CC1=CN(C=N1)CCc2cnc(Nc3ccc(F)cc3)nc2C(F)(F)F | | InChIKey | XJXKZVQWZKYJGT-UHFFFAOYSA-N | | Physical state | White crystalline solid; soluble in DMSO, moderately soluble in 0.5 % methylcellulose (pH 7.4) | | pKa (predicted) | 7.6 (basic imidazole) | | LogP (XlogP3-AA) | 3.1 (moderately lipophilic) | If you’re curious about the next generation of

The above physicochemical data are derived from the original patent and the ChemDraw‑generated descriptors in the ChEMBL entry (CHEMBL657891).

JUQ‑934 is a novel, orally bioavailable small‑molecule that has attracted attention as a potential therapeutic in oncology and immunology. First disclosed in a 2023 patent filing (WO 2023/178965 A1) and subsequently presented in several conference abstracts (AACR 2024, ASCO 2025), JUQ‑934 belongs to a new chemotype of bromodomain‑extra‑terminal (BET) protein antagonists with a unique “hinge‑binding” motif that confers high selectivity for BRD4 over BRD2/BRD3 and reduced off‑target activity on kinases. Stay tuned to TechFrontiers for deep‑dives into the

Because the compound is still pre‑clinical, most of the data available are from in‑vitro assays, cell‑based pharmacology, and early animal efficacy studies. This review collates all publicly accessible information, critically evaluates the current state of knowledge, and outlines the key questions that must be addressed before JUW‑934 can advance to human trials.